Acorda, Biogen clinch licensing deal (Dealscape

Acorda Therapeutics Inc. of Hawthorne, N.Y. said Wednesday it has sold partial rights to its experimental multiple sclerosis drug to Biogen Idec Inc. for $110 million.

The initial fee is uncommonly large for a biotech licensing deal. Only a handful of up-front payments top $100 million each year, an indication that the drug Fampridine-SR has a good chance of coming to market. Biogen Idec gains all commercial rights outside the United States. Fampridine-SR has completed Phase 3 trials and has entered the European regulatory process for approval, though it's unclear if it will gain clearance this year. Acorda keeps U.S. rights. The Food and Drug Administration said it would finish its regulatory review in October.

This is a free content preview. Subscribers enjoy access to all stories in full as well as second-to-none market intelligence.

Dig deeper, with Pipeline.

815 in-depth reports of M&A deals in the Healthcare sector
96 company pages related to Biotechnology
31 articles related to Acorda Therapeutics Inc.
13 in-depth transaction records for Biogen
10 years of news and analysis archives from the voice of The Deal Economy

Most searched keywords

Deutsche Bank
Birds Eye
Cadbury AG
Agrium Inc.
Skadden Arps
Revolution Money
Tandberg ASA
Aisling Capital
Ken Lewis
Natco

Forward-looking intelligence allows you time to act. View this video on our restructuring content to see how you can benefit from our expertise.
NOT A SUBSCRIBER? Acorda, Biogen clinch licensing deal Posted on July 1, 2009 5:38 PM Acorda Therapeutics Inc. of Hawthorne, N.Y. said Wednesday it has sold partial rights to its experimental multiple sclerosis drug to Biogen Idec Inc. for $110 million. The initial fee is uncommonly large for a biotech licensing deal. Only a handful of up-front payments top $100 million each year, an indication that the drug Fampridine-SR has a good chance of coming to market. Biogen Idec gains all commercial rights outside the United States. Fampridine-SR has completed Phase 3 trials and has entered the European regulatory process for approval, though it's unclear if it will gain clearance this year. Acorda keeps U.S. rights. The Food and Drug Administration said it would finish its regulatory review in October. This is a free content preview. Subscribers enjoy access to all stories in full as well as second-to-none market intelligence. Dig deeper, with Pipeline. 815 in-depth reports of M&A deals in the Healthcare sector 96 company pages related to Biotechnology 31 articles related to Acorda Therapeutics Inc. 13 in-depth transaction records for Biogen 10 years of news and analysis archives from the voice of The Deal Economy Most searched keywords Deutsche Bank Birds Eye Cadbury AG Agrium Inc. Skadden Arps Revolution Money Tandberg ASA Aisling Capital Ken Lewis Natco		EXISTING USERS Username Password Forget your password? Missing a product?

Sales Contact Michael Crosby mcrosby@thedeal.com 212.313.9325	Media Contact Martha Brown mbrown@thedeal.com 212.313.9218
Signing in signifies that you agree to our terms and conditions. View our privacy policy.